EnsoData expands access to clinical data
By HME News Staff
Updated 12:40 PM CDT, Wed July 10, 2024
MADISON, Wis. – EnsoData has acquired sleep testing diagnostic technology from Resonea, adding acoustic flow and microphone data channels to its platform as a new way to use a mobile application to pre-screen patients for sleep apnea and extend the diagnostic capabilities of home sleep testing. These two new channels use a U.S. Food and Drug Administration-cleared app to record auditory data during sleep, securely transfer that data to the cloud and enable breath-by-breath analysis of respiratory flow and snoring to identify events indicative of sleep apnea or other disorders. “We are very excited to bring both acoustic flow and microphone data to the sleep community to expand the clinical data available for the health systems and providers utilizing PPG-based sleep testing,” said Justin Mortara, EnsoData CEO. “This is another step toward simplifying access to sleep care, helping to get more patients with sleep disorders diagnosed and, ultimately, connected with therapy. As a leader in health care AI solutions, EnsoData’s device agnostic approach using pulse oximeters (PPG) and now smartphones supports our strategy to deploy flexible solutions that can easily scale to address the unmet clinical needs for sleep testing in the U.S. and globally.” EnsoData expects to make the new capabilities commercially available in the U.S. this year.
Comments